Mirion’s third quarter was marked by robust demand across its core nuclear and medical safety markets, resulting in revenue growth that surpassed Wall Street expectations. Orders grew sharply, particularly in the nuclear power segment, with management highlighting “an impressive 105% increase” in nuclear power orders, excluding acquisitions. CEO Thomas D. Logan attributed the performance to strong backlog conversion and large project wins, noting that the company’s expanding backlog is “doing what is expected: converting into accelerated revenue.” The positive reception from investors reflects confidence in Mirion’s ability to capitalize on sector tailwinds and its execution in turning order momentum into top-line results.
Is now the time to buy MIR? Find out in our full research report (it’s free for active Edge members).
Mirion (MIR) Q3 2026 highlights:
- Revenue $277.8 million vs S&P analysts’ estimates of $274.9 million (24.5% year-on-year growth, 1.1% beat)
- Adjusted EPS $0.12 vs S&P analysts’ estimates of $0.12 (in line)
- Adjusted EBITDA $64.8 million vs analyst estimates of $69.04 million (23.3% margin, 6.1% miss)
- Adjusted EPS guidance Management slightly raised its full-year adjusted EPS guidance to $0.52 at the midpoint
- EBITDA guidance $288.5 million at the midpoint for the full year, in line with analyst expectations
- Operating margin 6.1%, up from 3.8% in the same quarter last year
- Market capitalization $4.02 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Mirion’s Q3 earnings call
- Tomo Sano (JPMorgan) asked about the sustainability of margin expansion in the nuclear business despite current headwinds, and CEO Thomas D. Logan explained that while near-term margins are tempered by AI and Paragon integration, annual expansion remains a target.
- Quinn Fredrickson (Baird) sought details on the timing and expected returns from AI investments, with Logan outlining a multi-phase approach focused on data infrastructure, internal productivity, and customer-facing products but noting benefits are still front-loaded in costs.
- Joe Ritchie (Goldman Sachs) probed the mix and timing of backlog conversion, and CFO Brian Schopfer confirmed that much of the backlog is expected to convert in the near term, not just over multiple years, supporting revenue visibility.
- Nicholas Amicucci (Evercore ISI) questioned the use of free cash flow for share repurchases versus deleveraging, and Schopfer emphasized that reducing leverage below 3x is a near-term priority but additional repurchases remain on the table.
- Morgan Stanley analyst inquired about Mirion’s ability to offset input cost inflation within its backlog, with Schopfer highlighting procurement programs and escalation clauses in contracts to mitigate inflationary pressures.
Catalysts in upcoming quarters
In the coming quarters, our analyst team will be watching (1) the pace of backlog conversion into revenue, particularly in nuclear power and large government projects; (2) the impact of continued AI and cybersecurity investments on both product development and operating margins; and (3) evidence of sustained order momentum from U.S. and European nuclear life extension and digital upgrade projects. Execution on medical segment recovery and the integration of recent acquisitions will also be key markers of progress.
Mirion currently trades at $16.70, up from $15.36 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
